{"entity":{"id":"cynk-001","kind":"drug","name":"CYNK-001","aka":["placental-derived natural killer (CYNK) cells"],"tldr":"CYNK-001 is an experimental allogeneic, cryopreserved, off-the-shelf natural killer cell therapy derived from placental haematopoietic stem cells from Celularity, in phase 1 trials for acute myeloid leukaemia, glioblastoma and multiple myeloma; its current status is not stated.","summary":"CYNK-001 (placental-derived natural killer (CYNK) cells) is an allogeneic, cryopreserved, off-the-shelf natural killer (NK) cell therapy derived from placental haematopoietic stem cells from Celularity. Ready-made NK cells grown from placental stem cells; the company reports killing of myeloma, AML and glioblastoma cells in the laboratory. Its furthest stage is phase 1, for acute myeloid leukaemia, glioblastoma and multiple myeloma. ClinicalTrials.gov registers it in 4 studies linked below. Cancer trials ended: AML NCT04310592 terminated ('Business reasons'), glioblastoma NCT04489420 terminated ('Business decision.'), glioblastoma NCT05218408 withdrawn, myeloma NCT04309084 status unknown. The company now describes CYNK-001 as a potential treatment for age-related diseases, and its current pipeline page does not list it. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Celularity: celularity.com","url":"https://celularity.com/nk-cell-platform/"},{"label":"Celularity: celularity.com","url":"https://celularity.com/nk-cell-platform/"},{"label":"Celularity: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04310592"},{"label":"Celularity: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04489420"},{"label":"ClinicalTrials.gov: trials of CYNK-001","url":"https://clinicaltrials.gov/search?intr=CYNK-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","glioblastoma","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["celularity"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04310592","nct04489420","nct04309084","nct05218408"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CYNK-001","modality":"Allogeneic, cryopreserved, off-the-shelf natural killer (NK) cell therapy derived from placental haematopoietic stem cells","mechanism":"Ready-made NK cells grown from placental stem cells; the company reports killing of myeloma, AML and glioblastoma cells in the laboratory.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cynk-001/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"celularity","kind":"company","name":"Celularity","route":"/companies/celularity/"}],"trial":[{"id":"nct05218408","kind":"trial","name":"CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type","route":"/trials/nct05218408/"},{"id":"nct04310592","kind":"trial","name":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","route":"/trials/nct04310592/"},{"id":"nct04309084","kind":"trial","name":"Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma","route":"/trials/nct04309084/"},{"id":"nct04489420","kind":"trial","name":"Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM","route":"/trials/nct04489420/"}]}}